AI Summary
This article discusses the use of cellular membrane-derived nanovesicles expressing hCD64 for targeting prostate cancer. The nanovesicles are engineered to specifically target prostate cancer cells, potentially improving the effectiveness of treatment. This research has significant implications for the development of targeted therapies for prostate cancer and may lead to more precise and efficient treatment strategies in the future.